What secondary cancer risk has been reported following treatment with radiation and antineoplastic agents such as dactinomycin?

An increased incidence of secondary primary tumours, including leukaemia, has been reported following radiation and antineoplastic agents such as Cosmegen (dactinomycin), requiring careful, long-term observation of cancer survivors after multimodal therapy.